Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2017 / Article
Special Issue

Dietary Supplements/Antioxidants: Impact on Redox Status in Brain Diseases

View this Special Issue

Review Article | Open Access

Volume 2017 |Article ID 7039816 | https://doi.org/10.1155/2017/7039816

Giulia Abate, Mariagrazia Marziano, Wiramon Rungratanawanich, Maurizio Memo, Daniela Uberti, "Nutrition and AGE-ing: Focusing on Alzheimer’s Disease", Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 7039816, 10 pages, 2017. https://doi.org/10.1155/2017/7039816

Nutrition and AGE-ing: Focusing on Alzheimer’s Disease

Academic Editor: Musthafa Mohamed Essa
Received27 Jul 2016
Revised28 Sep 2016
Accepted29 Sep 2016
Published12 Jan 2017


Recently, the role of food and nutrition in preventing or delaying chronic disability in the elderly population has received great attention. Thanks to their ability to influence biochemical and biological processes, bioactive nutrients are considered modifiable factors capable of preserving a healthy brain status. A diet rich in vitamins and polyphenols and poor in saturated fatty acids has been recommended. In the prospective of a healthy diet, cooking methods should be also considered. In fact, cooking procedures can modify the original dietary content, contributing not only to the loss of healthy nutrients, but also to the formation of toxins, including advanced glycation end products (AGEs). These harmful compounds are adsorbed at intestinal levels and can contribute to the ageing process. The accumulation of AGEs in ageing (“AGE-ing”) is further involved in the exacerbation of neurodegenerative and many other chronic diseases. In this review, we discuss food’s dual role as both source of bioactive nutrients and reservoir for potential toxic compounds—paying particular attention to the importance of proper nutrition in preventing/delaying Alzheimer’s disease. In addition, we focus on the importance of a good education in processing food in order to benefit from the nutritional properties of an optimal diet.

1. Introduction

Ageing is a major risk factor for chronic disease. Progressive decline of biological functions can render the organism more susceptible to endogenous or exogenous triggers, exacerbating pathological conditions. Among the age-related diseases, cognitive fragility and dementia remain the more debilitating, with a pronounced impact on public health costs arising from the need for long-term care management.

Policies that allow for the effective management of dementia include better coordination between health and long-term care services. However, the main goal should be to adopt proper strategies to preserve cognitive status and/or delay cognitive deterioration.

The degree of disability, including cognitive fragility, depends not only on genetic susceptibility, but also on lifestyle, environment, and triggers to which one is exposed [1, 2]. Appropriate lifestyle behaviours, including good nutrition and physical activity throughout life, are the first steps in preventing chronic diseases and disabilities in old age [2, 3]. Today it is well recognised that certain nutrients derived from the diet, including polyunsaturated fatty acids and polyphenolic compounds contained in fruits and vegetables, can dramatically impact the ageing brain, possibly leading to improved cognition and motor abilities. All these compounds exert potent antioxidant and anti-inflammatory activity. However, their potential for improving cognition is not limited to their antioxidant properties, as they also involve specific molecular and cellular processes that support brain plasticity [4]. For example, neuronal plasticity improvement by omega-3 intake was found to be mediated by the upregulation of brain-derived neurotrophic factor (BDNF) [4, 5].

Although a healthy diet takes into account different types of food as sources of bioactive nutrients able to preserve biological functions and prevent disease development, the contribution of different food processing and cooking methods is often poorly considered. Indeed, the technical manipulation of raw materials, industrial processing, and storage and cooking methods can modify food’s original contents. This contributes not only to the loss of healthy nutrients, but also to the formation of toxins—including advanced glycation end products (AGEs) [6].

Thus, this work reviewed the impact of nutrition on Alzheimer’s disease, the most common type of dementia, reporting knowledge on both the contribution of bioactive nutrients in preserving an active and healthy cognitive state, as well as the detrimental effects of dietary-glycotoxin, derived from food processing and cooking methods. In addition, we focus on the importance of a good education in processing food in order to benefit from the nutritional properties of an optimal diet.

2. Alzheimer’s Disease

Today, nearly 46.8 million worldwide people developed dementia, and the incidence is expected to rise in the coming years, with 74.7 million cases estimated to occur in 2030 and 131.5 million in 2050. After the age of 65, the risk of developing dementia doubles every five years, and Alzheimer’s disease (AD) affects one in four people aged 85 and over [7]. Alzheimer’s disease is a neurodegenerative disorder characterised by progressive global deterioration in intellect, which affects memory, thought, learning, orientation, language, comprehension, and judgment, as well as behaviour and the ability to perform everyday activities. The major pathological hallmarks of this disease include accumulation of protein deposits in the brain as beta-amyloid (Aβ) plaques and neurofibrillary tangles [8, 9]. In addition, an AD brain exhibits constant evidence of oxidative stress-mediated injury and widespread inflammation [10].

Alzheimer’s disease is a disorder of late life; however, there are families in which AD is inherited as an autosomal dominant disorder of midlife. Less than 1% of cases are caused by specific mutations in three genes, which code for amyloid-precursor protein (APP), Presenilin 1 and Presenilin 2, all linked to amyloid-beta metabolism [9].

AD has to face two major challenges: the delay in the diagnosis and the lack of neuroprotective or curative pharmacological treatment. In fact, AD is recognised only in the late stage when cognitive symptoms appear, and currently approved drugs only provide modest and temporary relief for symptoms such as memory loss. Today, it is well accepted that a prodromal phase ranging from 10 to 20 years precedes the symptomatic state. During this long period, many biochemical changes occur in the brain, anticipating cognitive impairment. In this preclinical phase, preventive strategies, such as dietary modification and nutritional supplementation, might reduce the global burden of AD. One of the first links between dietary intake and incidence of AD is represented by a large prospective population-based cohort study (Rotterdam study) that reported an associated lower risk with the use of cholesterol-lowering statin drug [11]. The association of dietary fats with plasma cholesterol levels is highly relevant because cholesterol is involved in both generation and deposition of Aβ [12]. Furthermore, the protein product of APOE-ε4, a recognised genetic risk factor for AD, is the principal cholesterol transporter in the brain. In fact, many epidemiologic data suggest that nutritional intake can influence the development and progression of AD [13].

3. Positive Effects of Dietary Nutrients in Preventing Cognitive Deterioration

A nutritional approach to prevent, delay, or halt the progression of AD is considered to be a promising strategy and has therefore been widely explored [14, 15].

3.1. Polyunsaturated Fatty Acids

Numerous studies have investigated the effects of polyunsaturated fatty acids (PUFAs) in preventing and/or slowing AD. The potential PUFA dietary intervention to prevent neuronal loss and cognitive decline stems from evidence that PUFAs are critical components of neuronal cell membranes, maintaining membrane fluidity, which is essential for synaptic vesicle fusion and neurotransmitter communication within neural networks. The n-3 long chain PUFAs (n-3 LCPUFAs), which mainly include omega-3, docosahexanoic acid (DHA), and eicosapentaenoic acid (EPA), regulate neuronal membrane excitability and improve the capacity for neuronal transmission in healthy subjects, thus enhancing learning and memory [16]. Furthermore, DHA, whose high levels in brain indicate its essential role in this organ, is also involved in mood and emotional state, locomotor and exploratory activities, and cognitive functions [17].

In addition, n-3 LCPUFAs modulate the inflammatory processes by acting at the immune system level in many different ways through (i) the regulation of cytokines and chemokines expression, (ii) the decrease of prostaglandins and eicosanoids, and (iii) the induction of proresolutive factors, resolvins, and protectins that are involved in the resolution of inflammation [5, 17, 18]. EPA, DHA, and their bioactive mediators exert their anti-inflammatory effects not only in the periphery [19] but also at the brain level [20]. Interestingly, Freund Levi et al. [21] demonstrated that a diet rich in n-3 LCPUFAs significantly increased DHA levels in the brain, suggesting that DHA and EPA dietary supplementation might directly influence neuroinflammatory pathways [20].

Numerous observational studies have highlighted a possible association between dietary intake of fish and n-3 LCPUFA and a lower risk of dementia, including AD [13, 22, 23]. On the other hand, it has to be stressed that studies finding limited or no clinical benefit of PUFAs on cognitive improvement in AD patients were also reported [24, 25]. For example, Chiu et al. [26] have demonstrated in a double-blind placebo-controlled study that omega-3 monotherapy improved cognitive performance only in Mild Cognitive Impairment (MCI) patients but not in AD group. The reasons why no effect of omega-3 treatment was observed in patients with moderate or advanced AD could be due to the relatively short duration of the supplementation, the daily dose used, the source and the origin (fish versus vegetable oil) of n-3 LCPUFA, the dietary history of the patients, and the cognitive function assessed [18, 27]. Therefore, Hooijmans et al. [28] performed a meta-analysis study on the effects of long-term omega-3 supplementation in AD animal models, confirming its well-recognised effect in restoring cognitive performance. In particular, long-term omega-3 supplementation decreased omega-6/omega-3 ratio, reduced the amount of beta-amyloid, prevented neuronal loss, and improved cognitive function in AD animal models. Furthermore, the effects of DHA in reducing Aβ production in in vitro study and AD animal models have been also widely demonstrated [29, 30]. The mechanism involved in the DHA-induced reduction in Aβ may be due to multiple effects: changing in lipid raft structure, alterations in APP processing, and induction of antiamyloidogenic chaperones for APP [31]. Data accumulated so far strongly suggest that the optimization of brain lipid profile might translate into a realistic strategy to enhance cognitive performance and/or to prevent neurodegenerative disorders. Therefore, in the years to come, research effort has to be devoted to define the optimal lipid dietary intake for the ageing brain and who might benefit the most from it [17].

3.2. Vitamins

Vitamins are potent antioxidants. Their potentiality in maintaining healthy cognition and preventing cognitive decline rises by the fact that the brain is particularly susceptible to oxidative stress damage. The brain is a major metaboliser of oxygen, accounting for 20% of the body’s consumption, and has relatively feeble protective antioxidant mechanisms. In addition, it contains a large amount of polyunsaturated peroxidisable fatty acids, along with high levels of iron that act as a prooxidant. A free radical-enriched environment in the brain contributes to the progressive decline of cognitive abilities, exacerbating dementia. Vitamin E has been intensively investigated for its role in protecting membrane phospholipids against peroxidation. Zandi et al. [32] demonstrated that the use of vitamin E and vitamin C supplements in combination with food is associated with reduced prevalence and incidence of AD. A multicentre clinical trial on vitamin E supplementation for patients with moderate AD demonstrated that vitamin E slowed disease progression, thereby reducing the risk of institutionalisation [32, 33]. However, in another study, no significant differences in progression of AD were found in the vitamin E group compared to the placebo group [33]. This is probably due to the different compositions of vitamin E supplements, which often differ from the form of vitamin E found in the diet. Vitamin E refers to a group of fat-soluble compounds that include eight chemical forms. Among them, γ-tocopherol and α-tocopherol are the most abundant in the diet, and α-tocopherol is also the one that exerts antioxidant properties [34]. In this context, Grimm et al. [35] demonstrated that δ-tocopherol, but not α-tocopherol, increased the level of Aβ by enhancing its production and decreasing its degradation, worsening the pathology. Another critical issue to solve is the optimal dose of vitamin E required to prevent or delay AD. Therefore, more clinical trials are needed to define the proper vitamin E composition and dosage in the treatment of this pathology.

Vitamin D might also have an association with AD. Observational studies offer good evidence that low vitamin D concentration is a risk factor for developing AD, because its concentrations have been found inversely correlated with its risk [36]. Thus, wishing to reduce risk of AD, the Endocrine Society recommendations of keeping vitamin D3 concentrations above 75 nmol/L [36, 37] should be considered.

Furthermore, polymorphism of the vitamin D receptor (VDR) and altered vitamin D signalling have been found to predispose to AD development or AD-like neurodegeneration [38]. Interestingly, in the transgenic 5xFAD (Tg) mice, an animal model of AD, five months of vitamin D3 supplementation enhanced learning and memory [39]. This treatment has been demonstrated to induce the expression of proteins involved in the immune and inflammatory response, neurotransmitter activity, and endothelial and vascular processes, with a significant decrease of amyloid plaques and astrogliosis. Recently, Gangwar et al. [40] suggested that vitamin D supplementation induced significant improvement in cognitive performances also in subjects with senile dementia.

Other vitamins, including vitamin A and the complex of vitamin B, were found lower in plasma/serum of geriatric patients with cognitive impairment [41, 42]. For their role in homocysteine metabolism, the three B vitamins (B6, B12, and folic acid) have been correlated with age-related cognitive fragility [43]. Previous epidemiological studies on vitamin B and cognitive status found that older people with elevated homocysteine levels (hyperhomocysteinaemia) tend to have lower vitamin B status, as well as lower cognitive tests scores [44]. Possible correlations between vitamin A and Alzheimer’s disease were reported in in vitro studies, demonstrating an anti-beta-amyloid oligomerization effect of vitamin A and beta-carotene [45]. However, more clinical work is needed to identify the potential benefit from vitamin A and/or complex B supplementation in AD patients.

3.3. Polyphenols

The beneficial role of dietary polyphenols has been suggested as potential functional food candidates to prevent memory decline [46]. Polyphenols are natural substances present in plants, fruits, and vegetables. Some polyphenols, such as epigallocatechin-3-gallate (EGCG) found in green tea, 4-O-methyl honokiol found in Magnolia officinalis, resveratrol contained in grapes, and ginkgolide A found in ginkgo biloba, have been suggested to provide protection against AD. Their effects may be due to their antioxidant and anti-inflammatory properties, but also by their modulation of enzyme activity and regulation of intracellular signalling pathways and gene expression [46, 47].

In fact, polyphenols, especially flavonoids, can also modulate those neuronal signalling cascades altered with ageing by acting on ERK/CREB pathway involved in synaptic plasticity and long-term potentiation, improving learning and memory in both animals and humans [4851]. Flavonoid supplementations can modulate specific signalling kinases like CaMKII and ERK, controlling the activation of CREB and the increased expression of BDNF and NGF at the brain level [5052]. In fact, these compounds also exert a protective function in the hippocampus of middle age mice preserving and promoting the spatial learning strategies. Recently also Bensalem et al. [53] demonstrated that a polyphenol-rich extract from grape and blueberry (PEGB), with high contents of flavonoids, can facilitate the use of spatial strategies in both adult and middle-aged mice. In these animals PEGB supplementation was able to improve learning performance by restoring CaMKII mRNA levels and increasing NGF expression exactly in the hippocampus. It is noteworthy that this is the first nutritional intervention that, even if with a mix of different polyphenols at low doses, shows a rescue effect on those specific memory deficits [53].

Furthermore, Ono et al. [54] have further corroborated the relevance of polyphenol supplementation for AD prevention. He demonstrated that wine-related polyphenols, including myricetin, quercetin, and kaempferol, inhibited Aβ oligomer formation in a dose-dependent manner from fresh monomeric Aβ, as well as destabilised preformed Aβ oligomers in in vitro experiments. Resveratrol, another wine-related polyphenol abundant also in berries, protects neurons against Aβ-induced toxicity and attenuates behavioural impairment in rats [55]. Again, green tea’s polyphenols, EGCG and epicatechin (EC), showed their neuroprotective effects throughout the free radical scavengers on in vitro oxidative stress and in neurotoxicity cellular models [56, 57].

Curcumin also has a potential role in the prevention and treatment of AD. The biophenolic curcumin, isolated as the active yellow component of Curcuma longa, has a long history of use in traditional Asian medicines for its potent anti-inflammatory, antioxidant, and anticancer activities [58]. In AD animal models, curcumin reduced proinflammatory cytokines, oxidative damage, and beta-amyloid production, ameliorating cognitive deficits [59]. Zhang et al. [60] demonstrated that macrophages derived from AD patients treated with curcumin showed an improved uptake of beta-amyloid when compared with untreated cells. In addition, curcumin exerted an antiproliferative action on microglial cells preventing cytokine release. Also Ambegaokar et al. [61], using different doses of curcumin in a mixed colony of both neuronal and glial rat cells, showed that curcumin stopped the proliferation of neuroglial cells dose dependently, by differentiating them into mature cells or inducing apoptosis, resulting in inhibiting neuroinflammation. Furthermore, curcumin decreases the lipoprotein oxidation and the free radicals formation in AD and in other neurodegenerative disorders [62]. Because of its lipophilic nature, curcumin crossed the blood-brain barrier and reduced existing senile plaques, as demonstrated in APPswe/PS1dE9 mice [63]. Curcumin reduces senile plaques by binding with the Aβ oligomers, destabilising them and preventing their extension [64]. However, further studies on large population will be necessary in order to demonstrate the effects of all these polyphenols in delaying or preventing AD.

4. Dietary-Advanced Glycation End Products (d-AGEs) and Cognitive Decline

During the processing of foods, the temperature, the duration of the heat treatment, and the food’s water content can drive different biochemical reactions, transforming the original content. At high heat administered for a long period of time, we expect the loss of a high amount of water and the degradation of heat-sensitive micronutrients, such as vitamin C, folates, and thiamine. In addition, higher temperatures used for cooking induce a series of reactions that lead to the characteristic smell, taste, and colour of the dish. Those reactions are also involved in the formation of toxic secondary products known as advanced glycation end products (AGEs). AGEs are a heterogeneous group of compounds derived from a nonenzymatic glycation of free amino groups of proteins, lipids, or nucleic acids by reducing sugars and reactive aldehydes [65]. They are also continuously formed in the body as a part of normal metabolism under hyperglycaemic and/or oxidative stress conditions [6, 65]. It is well known that AGEs derived from the diet can highly contribute to the body pool of AGEs and constitute a large amount of the total AGE serum content. Since the half-life of AGEs is about double the average of a cell’s life, their detrimental effects can persist for a long time, especially in “long-lived” cells like nerve and brain cells [66]. Their toxic effects are related to their ability to promote oxidative stress and inflammation by binding to cell surface receptors or cross-linking with body proteins, altering their structure and function [67, 68].

The most studied AGE receptor is RAGE, a single transmembrane multiligand receptor that belongs to the immunoglobulin superfamily [69]. RAGE receptors are mainly expressed on vascular, endothelial, and smooth muscle cells and on monocyte/macrophage membranes [69], but also in microglia and astrocytes, as well as in neurons [70, 71]. Ligands of RAGE, apart from AGEs, include members of the S100 protein family, proteins of the high mobility group box-1 (HMGB1), prions, and amyloid-β peptides. RAGE is implicated in the pathogenesis of several chronic diseases, such as cardiovascular diseases, hypertension, and diabetes, which are risk factors for AD, suggesting it might be the molecular link that initiates a chronic positive feedback loop, ultimately leading to AD etiology [69].

The interaction of RAGE receptors with AGEs induces the activation of different intracellular cascades, which involve the nuclear factor kB (NF-κB) pathway and inflammatory mediators like tumour necrosis factor-α (TNF-α), interleukin-6, and C-reactive protein (CRP) [72]. All of these pathways lead to increased oxidative stress and a proinflammatory status.

Recently, different studies reported that an elevated serum level of AGEs is associated with a faster rate of cognitive decline [66, 73]. More specifically, increasing evidence in the literature suggests that AGEs could be implicated in the progression of Alzheimer’s, Parkinson’s disease, and cerebrovascular dementia. In particular, RAGE seems to be involved in AGE-induced oxidative stress and chronic subclinical inflammation in the AD brain [74]. In fact, RAGE is increased in the brains of AD patients and has a role in regulating the transport of beta-amyloid across the blood-brain barrier (BBB) [75]. In particular, RAGE was found to act as cell surface receptor for Aβ [75, 76] and promote the influx of circulating Aβ across BBB from blood to brain, which is antagonized by LRP-1-mediated efflux of Aβ [77, 78]. The interaction of AGEs with their receptor (RAGE) activates also the proinflammatory pathway via NF-kB. The neuroinflammation induced by AGEs can establish a vicious circle, whereby the overregulation of RAGE potentially increases Aβ influx across the BBB, leading to an accumulation of Aβ in the brain [79]. Furthermore, in the last years, a newly role of RAGE is emerging in microglia activation. This can have some implication in AD pathogenesis [80]. In fact, the interaction of RAGE with Aβ in activated microglia can initiate a cascade of events, resulting in sustained generation of toxic mediators and, ultimately, exacerbating neuroinflammation and leading to neuronal loss [69].

Recently, Perrone et al. [81] also presented evidence for a novel RAGE-mediated signalling in AD, which leads to the expression of thioredoxin interacting protein (TXNIP) in various cell types, promoting inflammation [81, 82]. TXNIP binds to thioredoxin (TRX) and inhibits its antioxidant activity, leading to oxidative stress [83]. Among the many proteins under the redox control of TRX, the pleiotropic p53 was found peculiarly nitrated at its tyrosine residues in AD blood cells [84], suggesting that alteration of RAGE-TXNIP axis can have different downstream effects, contributing to the complexity of the disease. Notably, both TXNIP and RAGE may exacerbate injury and inflammation when chronically activated, while they mediate neuronal repair when transiently expressed [8183]. Therefore, the RAGE-TXNIP axis participates in AD progression by activating a concerted action of oxidative stress, inflammation, vascular dysfunction, and neurodegeneration. Thus, inhibition of chronic activation of RAGE and TXNIP might efficiently provide neuroprotection in AD [82].

Differently from RAGE, a protective role has been ascribed to its secreted isoform, sRAGE. sRAGE lacks the transmembrane domain and is present in human plasma, functioning as a “decoy,” binding Aβ in plasma and preventing neurotoxic or proinflammatory responses of RAGE–Aβ interaction in microglia and neurons [77, 85].

In addition, some authors have proposed an involvement of the imbalance in AGE clearance in AD pathology. The serum level of AGEs is the result of their endogenous production, exogenous dietary intake, and renal clearance. Several enzymes (glyoxalase I and II and carbonyl reductase) and a specific receptor (AGER1) are also involved in the detoxification system against the prooxidant effects of glycation [67, 68]. Interestingly, in the early stage of AD, glyoxalase I is upregulated in order to maintain α-oxoaldehyde products at a physiological level, while in the late stage the enzyme is decreased. The correlation between AGE deposits and glyoxalase I expression has been further demonstrated in both age- and AD-affected brains [86].

Food, as both source of bioactive nutrients and reservoir for potential toxic compounds, can have a dual role in AD pathology (Figure 1). All these findings indicate that AGEs can be considered as dietary risk factors not yet recognized and important pathogenic mediators involved in AD. The discovery of natural or pharmacological AGE inhibitors and the adoption of an AGE-restricted diet might be further new challenges, in order to promote a healthy ageing status and prevent cognitive decline exacerbation.

5. Dietary AGEs and Alzheimer’s Disease: Association or Causality

Since Uribarri and colleagues investigated AGE content in more than 500 dietary compounds [87, 88], cohort studies, investigating how defined dietary patterns affect AD incidence, may be revisited to extrapolate the correlation between dietary AGE content and AD progression. Perrone and Grant [89] in a very interesting ecological and observational study demonstrated that both the Mediterranean diet (MeDi) and the traditional Japanese diet help in preventing AD. Although the traditional Japanese diet differs markedly from the MeDi, it is also low in meat and dairy products, which contain a high level of AGEs, suggesting a strict correlation among lower meat intake, poor AGEs dietary, and reduced risk to develop AD [36, 89]. In Japan, the nutritional transition from the traditional Japanese diet to the Western diet in the last 25 years has led to an improved meat consumption with enhancement of meat-AGEs from 24% to 52% of the total dietary AGEs, while the AD prevalence increased from 1% to 7% in people over 65 years [8992]. However, whether the increase of Japanese AD cases could be due to the enhancement of meat consumption still has to be well clarified. In fact, it cannot be excluded that in the different examined cohort studies other risk-modifying factors (trace minerals in the brain [93], obesity rates [94], vitamin D concentrations [95], physical activity levels [96], and alcohol consumption rates [97]) could be also changed.

To evaluate whether dietary AGEs contribute to AD development or are just causally linked to risk of AD, Hill’s criteria for causality in a biological system have been examined [89]. These criteria consider the strength of association, consistent findings in different populations, temporality, biological gradient, plausibility (e.g., mechanisms), and experiment (e.g., randomized controlled trials or animal model studies) [89, 98]. In the context of dietary AGEs and AD risk, several of Hill’s criteria have been satisfied and clearly indicate that AGEs, mostly in association with increased meat consumption, can be considered risk-modifying factors for AD pathology [36, 89].

6. Good Tips for a Healthy Low-AGE Diet

Many studies have demonstrated that a high-AGE diet promotes oxidative stress and increases proinflammatory markers in chronic conditions and neurodegenerative diseases. The potential benefits of a restricted AGE diet are promising and could offer a simple alternative therapy in the prevention and treatment of these conditions. Over the past decade, several clinical trials have been performed demonstrating that the application of an AGE-restricted diet reduces not only the systemic levels of AGEs but also the levels of markers of oxidative stress and inflammation [87, 88]. The first line of action is to implement the use of food with the lowest AGE content—mainly food composed of carbohydrates (e.g., starches, fruits, and vegetables) instead of full-fat cheeses, meats, and highly processed foods. For the purpose of estimating dietary AGE intake, a large database has been published of the AGE content of the most common foods [88]. Currently, no official recommendations exist regarding the acceptable range or identifying the upper limit of dietary AGE intake. Different studies have shown that the average intake is nearly 15,000 KU/day in healthy individuals [99]. Uribarri et al. [100] have proposed that half of the current mean AGE intake, about 7,500 KU/day, could be a very realistic goal. A dietary AGE (d-AGEs) reduction of this magnitude has been found to significantly alter the levels of circulating AGEs and at the same time reduce levels of oxidative stress and inflammation markers, enhancing insulin sensitivity in diabetic patients [6568]. One of the difficulties with diets at lowest AGEs content is to maintain adequate content of other nutrients, in addition to the quality of an appetizing and tasty meal. For example, the ICARE clinical study performed by Pouillart et al. [101] compared two realistic and similar diets with different AGE levels to explore the possible health impact of dietary AGEs. The low-AGE diet, achieved by adjusting fat intake and increasing quantities of cooked vegetables and steam-cooked food, reduced oxidative and inflammatory markers in healthy subjects [100].

Cooking methods and the temperature used in cooking are two variables for reducing dietary AGE intake. Meat and meat-derived products processed using high, dry heat, such as in broiling, grilling, frying, and roasting, are major sources of d-AGEs. Alternative cooking methods, such as boiling and stewing, allow daily d-AGEs ingestion to be reduced by up to 50%, while still maintaining the same primary nutrients [99]. Uribarri et al. estimated that a 90 g chicken breast has an AGE amount of 1,000 KU when boiled, while the AGE content increases up to 9,000 KU if broiled [100]. The cooking time can also influence the AGE content. We recently demonstrated that overcooking Mediterranean pasta doubled the methylglyoxal content, compared to the content achieved with the suggested cooking time [102].

On the other hand, the sparing use of herbs, condiments, and spices like curcumin, cinnamon, parsley, thyme, and clove can prevent cooking-induced AGE formation. Dearlove and colleagues [103] demonstrated that polyphenols found in culinary herbs like sage, marjoram, tarragon, and rosemary are potent inhibitors of fructose-mediated protein glycation. Spice extracts, such as cloves, ground Jamaican allspice, and cinnamon, were also found to be glycation inhibitors, and to a greater extent compared to herb extracts [103]. In addition, AGE formation can be prevented by pretreating meat with an acidic solution like vinegar or lemon juice, which interferes with the dramatic increase in AGE formation during high heat exposure. For example, beef marinated for one hour in such a solution formed less than half the amount of AGEs during cooking than untreated samples [100]. Many other antioxidant bioactive nutrients have been demonstrated to have antiglycation activity. The inhibition of glycoxidation has been showed for various polyphenols, including quercetin, genistein, tannic acid, and gallic acid [104, 105]. Therefore, the consumption of a polyphenol-rich diet may attenuate protein glycation to some extent, and the addition of polyphenols can be useful in reducing undesired glycoxidation in food processing.

7. Conclusion

Over two thousand years ago, Hippocrates coined the phrase, “Let food be the medicine and medicine be the food.” Today, that message has been reinforced by rigorous scientific evidence and observational and ecological studies. Food scientists have demonstrated the peculiar value of specific nutrients present in food for improving cognitive status and preventing dementia. Furthermore, findings that secondary products derived from cooked food can accumulate over time in the body and represent potential risk factors for Alzheimer’s disease have provided newfound awareness of the importance of healthy cooking methods.

Currently, the effects of low-AGE diet in preserving cognitive ability in AD progression are not clearly understood yet. However, wishing that the reduction of dietary-glycotoxins and the intake of bioactive nutrients in preventing/delaying AD will be confirmed, nutritional intervention might be considered a promising strategy to reduce AD prevalence.

Competing Interests

The authors confirm that this article content has no conflict of interests.


This work has been supported by Ministry of University and Research (MIUR) Grants PAN LAB PON A3_00166.


  1. P. Sebastiani and T. T. Perls, “The genetics of extreme longevity: lessons from the new england centenarian study,” Frontiers in Genetics, vol. 3, article no. 277, 2012. View at: Publisher Site | Google Scholar
  2. M. Lövdén, W. Xu, and H.-X. Wang, “Lifestyle change and the prevention of cognitive decline and dementia: what is the evidence?” Current Opinion in Psychiatry, vol. 26, no. 3, pp. 239–243, 2013. View at: Publisher Site | Google Scholar
  3. T. Ahmed and N. Haboubi, “Assessment and management of nutrition in older people and its importance to health,” Clinical Interventions in Aging, vol. 5, pp. 207–216, 2010. View at: Google Scholar
  4. J. Reedy, S. M. Krebs-Smith, P. E. Miller et al., “Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, and cancer mortality among older adults,” The Journal of Nutrition, vol. 144, no. 6, pp. 881–889, 2014. View at: Publisher Site | Google Scholar
  5. P. C. Calder, “Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1851, no. 4, pp. 469–484, 2015. View at: Publisher Site | Google Scholar
  6. C. Prasad, V. Imrhan, F. Marotta, S. Juma, and P. Vijayagopal, “Lifestyle and advanced glycation end products (AGEs) burden: its relevance to healthy aging,” Aging and Disease, vol. 5, no. 3, pp. 212–217, 2014. View at: Publisher Site | Google Scholar
  7. Alzheimer's Disease International, World Alzheimer Report 2015, The Global Economic Impact of Dementia, 2015.
  8. K. Shoghi-Jadid, G. W. Small, E. D. Agdeppa et al., “Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease,” The American Journal of Geriatric Psychiatry, vol. 10, no. 1, pp. 24–35, 2002. View at: Publisher Site | Google Scholar
  9. D. J. Selkoe and J. Hardy, “The amyloid hypothesis of Alzheimer's disease at 25 years,” EMBO Molecular Medicine, vol. 8, no. 6, pp. 595–608, 2016. View at: Publisher Site | Google Scholar
  10. P. Agostinho, R. A. Cunha, and C. Oliveira, “Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease,” Current Pharmaceutical Design, vol. 16, no. 25, pp. 2766–2778, 2010. View at: Publisher Site | Google Scholar
  11. M. D. M. Haag, A. Hofman, P. J. Koudstaal, B. H. C. Stricker, and M. M. B. Breteler, “Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 1, pp. 13–17, 2009. View at: Publisher Site | Google Scholar
  12. H. L. Daneschvar, M. D. Aronson, and G. W. Smetana, “Do statins prevent Alzheimer's disease? A narrative review,” European Journal of Internal Medicine, vol. 26, no. 9, pp. 666–669, 2015. View at: Publisher Site | Google Scholar
  13. S. Gillette-Guyonnet, M. Secher, and B. Vellas, “Nutrition and neurodegeneration: epidemiological evidence and challenges for future research,” British Journal of Clinical Pharmacology, vol. 75, no. 3, pp. 738–755, 2013. View at: Publisher Site | Google Scholar
  14. E. M. van der Beek and P. J. G. H. Kamphuis, “The potential role of nutritional components in the management of Alzheimer's Disease,” European Journal of Pharmacology, vol. 585, no. 1, pp. 197–207, 2008. View at: Publisher Site | Google Scholar
  15. L. Nelson and N. Tabet, “Slowing the progression of Alzheimer's disease; what works?” Ageing Research Reviews, vol. 23, pp. 193–209, 2015. View at: Publisher Site | Google Scholar
  16. D. Vauzour, A. Martinsen, and S. Layé, “Neuroinflammatory processes in cognitive disorders: is there a role for flavonoids and n-3 polyunsaturated fatty acids in counteracting their detrimental effects?” Neurochemistry International, vol. 89, pp. 63–74, 2015. View at: Publisher Site | Google Scholar
  17. C. Joffre, A. Nadjar, M. Lebbadi, F. Calon, and S. Laye, “n-3 LCPUFA improves cognition: the young, the old and the sick,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 91, no. 1-2, pp. 1–20, 2014. View at: Publisher Site | Google Scholar
  18. P. C. Calder, “n-3 fatty acids, inflammation and immunity: new mechanisms to explain old actions,” Proceedings of the Nutrition Society, vol. 72, no. 3, pp. 326–336, 2013. View at: Publisher Site | Google Scholar
  19. C. N. Serhan and N. Chiang, “Resolution phase lipid mediators of inflammation: agonists of resolution,” Current Opinion in Pharmacology, vol. 13, no. 4, pp. 632–640, 2013. View at: Publisher Site | Google Scholar
  20. R. P. Bazinet and S. Layé, “Polyunsaturated fatty acids and their metabolites in brain function and disease,” Nature Reviews Neuroscience, vol. 15, no. 12, pp. 771–785, 2014. View at: Publisher Site | Google Scholar
  21. Y. Freund Levi, I. Vedin, T. Cederholm et al., “Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study,” Journal of Internal Medicine, vol. 275, no. 4, pp. 428–436, 2014. View at: Publisher Site | Google Scholar
  22. P. Barberger-Gateau, C. Samieri, C. Féart, and M. Plourde, “Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype,” Current Alzheimer Research, vol. 8, no. 5, pp. 479–491, 2011. View at: Publisher Site | Google Scholar
  23. P. Barberger-Gateau, C. Raffaitin, L. Letenneur et al., “Dietary patterns and risk of dementia: the Three-City cohort study,” Neurology, vol. 69, no. 20, pp. 1921–1930, 2007. View at: Publisher Site | Google Scholar
  24. C. Stough, L. Downey, B. Silber et al., “The effects of 90-day supplementation with the omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population,” Neurobiology of Aging, vol. 33, no. 4, pp. 824.e1–824.e3, 2012. View at: Publisher Site | Google Scholar
  25. Y. Freund-Levi, M. Eriksdotter-Jönhagen, T. Cederholm et al., “ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial,” Archives of Neurology, vol. 63, no. 10, pp. 1402–1408, 2006. View at: Publisher Site | Google Scholar
  26. C.-C. Chiu, K.-P. Su, T.-C. Cheng et al., “The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 6, pp. 1538–1544, 2008. View at: Publisher Site | Google Scholar
  27. A. D. Dangour and E. Allen, “Do omega-3 fats boost brain function in adults? Are we any closer to an answer?” The American Journal of Clinical Nutrition, vol. 97, no. 5, pp. 909–910, 2013. View at: Publisher Site | Google Scholar
  28. C. R. Hooijmans, P. C. M. Pasker-De Jong, R. B. M. De Vries, and M. Ritskes-Hoitinga, “The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: a systematic review and meta-analysis,” Journal of Alzheimer's Disease, vol. 28, no. 1, pp. 191–209, 2012. View at: Publisher Site | Google Scholar
  29. M. Oksman, H. Iivonen, E. Hogyes et al., “Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice,” Neurobiology of Disease, vol. 23, no. 3, pp. 563–572, 2006. View at: Publisher Site | Google Scholar
  30. C. R. Hooijmans, F. Rutters, P. J. Dederen et al., “Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD),” Neurobiology of Disease, vol. 28, no. 1, pp. 16–29, 2007. View at: Publisher Site | Google Scholar
  31. W. Stillwell, S. R. Shaikh, M. Zerouga, R. Siddiqui, and S. R. Wassal, “Docosahexaenoic acid affects cell signaling by altering lipid rafts,” Reproduction Nutrition Development, vol. 45, no. 5, pp. 559–579, 2005. View at: Publisher Site | Google Scholar
  32. P. P. Zandi, J. C. Anthony, A. S. Khachaturian et al., “Reduced risk of alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study,” Archives of Neurology, vol. 61, no. 1, pp. 82–88, 2004. View at: Publisher Site | Google Scholar
  33. M. W. Dysken, M. Sano, S. Asthana et al., “Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial,” JAMA—Journal of the American Medical Association, vol. 311, no. 1, pp. 33–44, 2014. View at: Publisher Site | Google Scholar
  34. N. Farina, M. G. E. K. N. Isaac, A. R. Clark, J. Rusted, and N. Tabet, “Vitamin E for Alzheimer's dementia and mild cognitive impairment,” Cochrane Database of Systematic Reviews, vol. 11, Article ID CD002854, 2012. View at: Google Scholar
  35. M. O. W. Grimm, C. P. Stahlmann, J. Mett et al., “Vitamin E: curse or benefit in Alzheimer’s disease? A systematic investigation of the impact of α-, γ- and δ-tocopherol on Aβ generation and degradation in neuroblastoma cells,” Journal of Nutrition, Health and Aging, vol. 19, no. 6, pp. 646–654, 2015. View at: Publisher Site | Google Scholar
  36. W. B. Grant, “Using multicountry ecological and observational studies to determine dietary risk factors for Alzheimer's disease,” Journal of the American College of Nutrition, vol. 35, no. 5, pp. 476–489, 2016. View at: Publisher Site | Google Scholar
  37. M. F. Holick, N. C. Binkley, H. A. Bischoff-Ferrari et al., “Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 12, pp. 1911–1930, 2011. View at: Publisher Site | Google Scholar
  38. A. Banerjee, V. K. Khemka, A. Ganguly, D. Roy, U. Ganguly, and S. Chakrabarti, “Vitamin D and Alzheimer's disease: neurocognition to therapeutics,” International Journal of Alzheimer's Disease, vol. 2015, Article ID 192747, 11 pages, 2015. View at: Publisher Site | Google Scholar
  39. V. Landel, P. Millet, K. Baranger, B. Loriod, and F. Féron, “Vitamin D interacts with Esr1 and Igf1 to regulate molecular pathways relevant to Alzheimer's disease,” Molecular Neurodegeneration, vol. 11, no. 1, article no. 87, 2016. View at: Publisher Site | Google Scholar
  40. A. K. Gangwar, A. Rawat, S. Tiwari, S. C. Tiwari, J. Narayan, and S. Tiwari, “Role of vitamin-D in the prevention and treatment of Alzheimer's disease,” Indian Journal of Physiology and Pharmacology, vol. 59, no. 1, pp. 94–99, 2015. View at: Google Scholar
  41. G. Raszewski, R. Chwedorowicz, A. Chwedorowicz, and K. G. Rothenberg, “Homocysteine, antioxidant vitamins and lipids as biomarkers of neurodegeneration in Alzheimer’s disease versus non-Alzheimer’s dementia,” Annals of Agricultural and Environmental Medicine, vol. 23, no. 1, pp. 193–196, 2016. View at: Publisher Site | Google Scholar
  42. H. Chen, S. Liu, L. Ji et al., “Associations between Alzheimer’s disease and blood homocysteine, vitamin B12, and folate: a case-control study,” Current Alzheimer Research, vol. 12, no. 1, pp. 88–94, 2015. View at: Publisher Site | Google Scholar
  43. K. Eagappan and S. Sasikumar, “Functional nutrition is a deterimental factor in biological aging,” International Journal of Pharmaceutical Sciences Review and Research, vol. 32, no. 1, article 27, pp. 153–161, 2015. View at: Google Scholar
  44. S. J. Duthie, L. J. Whalley, A. R. Collins, S. Leaper, K. Berger, and I. J. Deary, “Homocysteine, B vitamin status, and cognitive function in the elderly,” The American Journal of Clinical Nutrition, vol. 75, no. 5, pp. 908–913, 2002. View at: Google Scholar
  45. J. Takasaki, K. Ono, Y. Yoshiike et al., “Vitamin A has anti-oligomerization effects on amyloid-β in vitro,” Journal of Alzheimer's Disease, vol. 27, no. 2, pp. 271–280, 2011. View at: Publisher Site | Google Scholar
  46. D.-Y. Choi, Y.-J. Lee, J. T. Hong, and H.-J. Lee, “Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease,” Brain Research Bulletin, vol. 87, no. 2-3, pp. 144–153, 2012. View at: Publisher Site | Google Scholar
  47. M. E. Obrenovich, N. G. Nair, A. Beyaz, G. Aliev, and V. P. Reddy, “The role of polyphenolic antioxidants in health, disease, and aging,” Rejuvenation Research, vol. 13, no. 6, pp. 631–643, 2010. View at: Publisher Site | Google Scholar
  48. R. J. Kean, D. J. Lamport, G. F. Dodd et al., “Chronic consumption of flavanone-rich orange juice is associated with cognitive benefits: an 8-wk, randomized, double-blind, placebo-controlled trial in healthy older adults,” The American Journal of Clinical Nutrition, vol. 101, no. 3, pp. 506–514, 2015. View at: Publisher Site | Google Scholar
  49. B. Shukitt-Hale, F. C. Lau, and J. A. Josep, “Berry fruit supplementation and the aging brain,” Journal of Agricultural and Food Chemistry, vol. 56, no. 3, pp. 636–641, 2008. View at: Publisher Site | Google Scholar
  50. C. Rendeiro, J. P. E. Spencer, D. Vauzour, L. T. Butler, J. A. Ellis, and C. M. Williams, “The impact of flavonoids on spatial memory in rodents: from behavior to underlying hippocampal mechanisms,” Genes and Nutrition, vol. 4, no. 4, pp. 251–270, 2009. View at: Publisher Site | Google Scholar
  51. S. De Nicoló, L. Tarani, M. Ceccanti et al., “Effects of olive polyphenols administration on nerve growth factor and brain-derived neurotrophic factor in the mouse brain,” Nutrition, vol. 29, no. 4, pp. 681–687, 2013. View at: Publisher Site | Google Scholar
  52. C. Rendeiro, A. Foley, V. C. Lau et al., “A role for hippocampal PSA-NCAM and NMDA-NR2B receptor function in flavonoid-induced spatial memory improvements in young rats,” Neuropharmacology, vol. 79, pp. 335–344, 2014. View at: Publisher Site | Google Scholar
  53. J. Bensalem, L. Servant, S. Alfos et al., “Dietary polyphenol supplementation prevents alterations of spatial navigation in middle-aged mice,” Frontiers in Behavioral Neuroscience, vol. 10, article no. 9, 2016. View at: Publisher Site | Google Scholar
  54. K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, and M. Yamada, “Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease,” Journal of Neurochemistry, vol. 87, no. 1, pp. 172–181, 2003. View at: Publisher Site | Google Scholar
  55. E. Younesi, “Evidence-based modeling of mode-of-action for functional ingredients influencing Alzheimer's disease through neurotrophin pathway,” Functional Foods in Health and Disease, vol. 4, no. 8, pp. 362–369, 2014. View at: Google Scholar
  56. M. Afzal, A. M. Safer, and M. Menon, “Green tea polyphenols and their potential role in health and disease,” Inflammopharmacology, vol. 23, no. 4, pp. 151–161, 2015. View at: Publisher Site | Google Scholar
  57. J. Cheng-Chung Wei, H.-C. Huang, W.-J. Chen, C.-N. Huang, C.-H. Peng, and C.-L. Lin, “Epigallocatechin gallate attenuates amyloid β-induced inflammation and neurotoxicity in EOC 13.31 microglia,” European Journal of Pharmacology, vol. 770, pp. 16–24, 2016. View at: Publisher Site | Google Scholar
  58. B. B. Aggarwal and K. B. Harikumar, “Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 1, pp. 40–59, 2009. View at: Publisher Site | Google Scholar
  59. S. A. Frautschy, W. Hu, P. Kim et al., “Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology,” Neurobiology of Aging, vol. 22, no. 6, pp. 993–1005, 2001. View at: Publisher Site | Google Scholar
  60. L. Zhang, M. Fiala, J. Cashman et al., “Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients,” Journal of Alzheimer's Disease, vol. 10, no. 1, pp. 1–7, 2006. View at: Google Scholar
  61. S. S. Ambegaokar, L. Wu, K. Alamshahi et al., “Curcumin inhibits dose-dependently and time-dependently neuroglial cell proliferation and growth,” Neuroendocrinology Letters, vol. 24, no. 6, pp. 469–473, 2003. View at: Google Scholar
  62. G.-Y. Kim, K.-H. Kim, S.-H. Lee et al., “Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-κB as potential targets,” Journal of Immunology, vol. 174, no. 12, pp. 8116–8124, 2005. View at: Publisher Site | Google Scholar
  63. M. Garcia-Alloza, L. A. Borrelli, A. Rozkalne, B. T. Hyman, and B. J. Bacskai, “Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model,” Journal of Neurochemistry, vol. 102, no. 4, pp. 1095–1104, 2007. View at: Publisher Site | Google Scholar
  64. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada, “Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro,” Journal of Neuroscience Research, vol. 75, no. 6, pp. 742–750, 2004. View at: Publisher Site | Google Scholar
  65. T. Goldberg, W. Cai, M. Peppa et al., “Advanced glycoxidation end products in commonly consumed foods,” Journal of the American Dietetic Association, vol. 104, no. 8, pp. 1287–1291, 2004. View at: Publisher Site | Google Scholar
  66. W. Cai, J. Uribarri, L. Zhu et al., “Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 13, pp. 4940–4945, 2014. View at: Publisher Site | Google Scholar
  67. O. Nedić, S. I. S. Rattan, T. Grune, and I. P. Trougakos, “Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology,” Free Radical Research, vol. 47, no. 1, pp. 28–38, 2013. View at: Publisher Site | Google Scholar
  68. J. Uribarri, M. D. del Castillo, M. P. de la Maza et al., “Dietary advanced glycation end products and their role in health and disease,” Advances in Nutrition, vol. 6, no. 4, pp. 461–473, 2015. View at: Publisher Site | Google Scholar
  69. C. Matrone, M. Djelloul, G. Taglialatela, and L. Perrone, “Inflammatory risk factors and pathologies promoting Alzheimer’s disease progression: is RAGE the key?” Histology and Histopathology, vol. 30, no. 2, pp. 125–139, 2015. View at: Google Scholar
  70. B.-R. Choi, W.-H. Cho, J. Kim et al., “Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease,” Experimental and Molecular Medicine, vol. 46, no. 2, article e75, 2014. View at: Publisher Site | Google Scholar
  71. E. C. W. van Straaten, D. Harvey, P. Scheltens et al., “Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia,” Journal of Neurology, vol. 255, no. 9, pp. 1302–1308, 2008. View at: Publisher Site | Google Scholar
  72. Z.-M. Shi, Y.-W. Han, X.-H. Han et al., “Upstream regulators and downstream effectors of NF-κB in Alzheimer's disease,” Journal of the Neurological Sciences, vol. 366, pp. 127–134, 2016. View at: Publisher Site | Google Scholar
  73. M. S. Beeri, E. Moshier, J. Schmeidler et al., “Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals,” Mechanisms of Ageing and Development, vol. 132, no. 11-12, pp. 583–587, 2011. View at: Publisher Site | Google Scholar
  74. P. Salahuddin, G. Rabbani, and R. H. Khan, “The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach,” Cellular and Molecular Biology Letters, vol. 19, no. 3, pp. 407–437, 2014. View at: Publisher Site | Google Scholar
  75. L.-F. Lue, D. G. Walker, L. Brachova et al., “Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism,” Experimental Neurology, vol. 171, no. 1, pp. 29–45, 2001. View at: Publisher Site | Google Scholar
  76. M. O. Chaney, W. B. Stine, T. A. Kokjohn et al., “RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1741, no. 1-2, pp. 199–205, 2005. View at: Publisher Site | Google Scholar
  77. F. Liang, J. Jia, S. Wang, W. Qin, and G. Liu, “Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease,” Journal of Clinical Neuroscience, vol. 20, no. 3, pp. 357–361, 2013. View at: Publisher Site | Google Scholar
  78. J. Provias and B. Jeynes, “The role of the blood-brain barrier in the pathogenesis of senile plaques in Alzheimer's disease,” International Journal of Alzheimer's Disease, vol. 2014, Article ID 191863, 7 pages, 2014. View at: Publisher Site | Google Scholar
  79. O. Arancio, H. P. Zhang, X. Chen et al., “RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice,” The EMBO Journal, vol. 23, no. 20, pp. 4096–4105, 2004. View at: Publisher Site | Google Scholar
  80. K. I. Mosher and T. Wyss-Coray, “Microglial dysfunction in brain aging and Alzheimer's disease,” Biochemical Pharmacology, vol. 88, no. 4, pp. 594–604, 2014. View at: Publisher Site | Google Scholar
  81. L. Perrone, T. S. Devi, K.-I. Hosoya, T. Terasaki, and L. P. Singh, “Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions,” Journal of Cellular Physiology, vol. 221, no. 1, pp. 262–272, 2009. View at: Publisher Site | Google Scholar
  82. L. Perrone, O. Sbai, P. P. Nawroth, and A. Bierhaus, “The complexity of sporadic Alzheimer's disease pathogenesis: the role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction,” International Journal of Alzheimer's Disease, vol. 2012, Article ID 734956, 13 pages, 2012. View at: Publisher Site | Google Scholar
  83. O. Sbai, T. S. Devi, M. A. B. Melone et al., “RAGE-TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression and cytokine secretion,” Journal of Cell Science, vol. 123, no. 24, pp. 4332–4339, 2010. View at: Publisher Site | Google Scholar
  84. L. Buizza, G. Cenini, C. Lanni et al., “Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease,” PLoS ONE, vol. 7, no. 1, Article ID e29789, 2012. View at: Publisher Site | Google Scholar
  85. S. J. Webster, S. Mruthinti, W. D. Hill, J. J. Buccafusco, and A. V. Terry Jr., “An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease,” NeuroMolecular Medicine, vol. 14, no. 2, pp. 119–130, 2012. View at: Publisher Site | Google Scholar
  86. B. Kuhla, K. Boeck, A. Schmidt et al., “Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains,” Neurobiology of Aging, vol. 28, no. 1, pp. 29–41, 2007. View at: Publisher Site | Google Scholar
  87. J. Uribarri, M. Peppa, W. Cai et al., “Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients,” Journal of the American Society of Nephrology, vol. 14, no. 3, pp. 728–731, 2003. View at: Publisher Site | Google Scholar
  88. J. Uribarri, W. Cai, M. Peppa et al., “Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging,” Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 62, no. 4, pp. 427–433, 2007. View at: Publisher Site | Google Scholar
  89. L. Perrone and W. B. Grant, “Observational and ecological studies of dietary advanced glycation end products in national diets and Alzheimer’s disease incidence and prevalence,” Journal of Alzheimer's Disease, vol. 45, no. 3, pp. 965–979, 2015. View at: Publisher Site | Google Scholar
  90. M. Ozawa, T. Ohara, T. Ninomiya et al., “Milk and dairy consumption and risk of dementia in an elderly Japanese population: the Hisayama Study,” Journal of the American Geriatrics Society, vol. 62, no. 7, pp. 1224–1230, 2014. View at: Publisher Site | Google Scholar
  91. M. Ozawa, T. Ninomiya, T. Ohara et al., “Dietary patterns and risk of dementia in an elderly Japanese population: the Hisayama Study,” American Journal of Clinical Nutrition, vol. 97, no. 5, pp. 1076–1082, 2013. View at: Publisher Site | Google Scholar
  92. N. D. Barnard, A. I. Bush, A. Ceccarelli et al., “Dietary and lifestyle guidelines for the prevention of Alzheimer's disease,” Neurobiology of Aging, vol. 35, no. 2, pp. S74–S78, 2014. View at: Publisher Site | Google Scholar
  93. A. I. Bush, “The metal theory of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 33, supplement 1, pp. S277–S281, 2013. View at: Publisher Site | Google Scholar
  94. L. Letra, I. Santana, and R. Seiça, “Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines,” Metabolic Brain Disease, vol. 29, no. 3, pp. 563–568, 2014. View at: Publisher Site | Google Scholar
  95. C. Balion, L. E. Griffith, L. Strifler et al., “Vitamin D, cognition, and dementia; a systematic review and meta-analysis,” Neurology, vol. 79, no. 13, pp. 1397–1405, 2012. View at: Publisher Site | Google Scholar
  96. K. I. Erickson, A. M. Weinstein, and O. L. Lopez, “Physical Activity, Brain Plasticity, and Alzheimer's Disease,” Archives of Medical Research, vol. 43, no. 8, pp. 615–621, 2012. View at: Publisher Site | Google Scholar
  97. A. K. Piazza-Gardner, T. J. B. Gaffud, and A. E. Barry, “The impact of alcohol on Alzheimer's disease: a systematic review,” Aging and Mental Health, vol. 17, no. 2, pp. 133–146, 2013. View at: Publisher Site | Google Scholar
  98. A. B. Hill, “The environment and disease: association or causation?” Journal of the Royal Society of Medicine, vol. 58, no. 5, pp. 295–300, 1965. View at: Publisher Site | Google Scholar
  99. K. Šebeková and V. Somoza, “Dietary advanced glycation endproducts (AGEs) and their health effects—PRO,” Molecular Nutrition and Food Research, vol. 51, no. 9, pp. 1079–1084, 2007. View at: Publisher Site | Google Scholar
  100. J. Uribarri, S. Woodruff, S. Goodman et al., “Advanced glycation end products in foods and a practical guide to their reduction in the diet,” Journal of the American Dietetic Association, vol. 110, no. 6, pp. 911–916.e12, 2010. View at: Publisher Site | Google Scholar
  101. P. Pouillart, H. Mauprivez, L. Ait-Ameur et al., “Strategy for the study of the health impact of dietary Maillard products in clinical studies: the example of the ICARE clinical study on healthy adults,” Annals of the New York Academy of Sciences, vol. 1126, pp. 173–176, 2008. View at: Publisher Site | Google Scholar
  102. G. Abate, A. Delbarba, M. Marziano et al., “Advanced Glycation End Products (AGEs) in Food: focusing on mediterranean pasta,” Journal of Nutrition & Food Sciences, vol. 5, article no. 440, 2015. View at: Publisher Site | Google Scholar
  103. R. P. Dearlove, P. Greenspan, D. K. Hartle, R. B. Swanson, and J. L. Hargrove, “Inhibition of protein glycation by extracts of culinary herbs and spices,” Journal of Medicinal Food, vol. 11, no. 2, pp. 275–281, 2008. View at: Publisher Site | Google Scholar
  104. L. Lv, X. Shao, H. Chen, C.-T. Ho, and S. Sang, “Genistein inhibits advanced glycation end product formation by trapping methylglyoxal,” Chemical Research in Toxicology, vol. 24, no. 4, pp. 579–586, 2011. View at: Publisher Site | Google Scholar
  105. I. Sadowska-Bartosz, S. Galiniak, and G. Bartosz, “Kinetics of glycoxidation of bovine serum albumin by methylglyoxal and glyoxal and its prevention by various compounds,” Molecules, vol. 19, no. 4, pp. 4880–4896, 2014. View at: Publisher Site | Google Scholar

Copyright © 2017 Giulia Abate et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

4635 Views | 2146 Downloads | 38 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.